Skip to main content
SpringerLink
Log in

Stellungnahme von DOG, RG und BVA zur therapeutischen Anwendung von voretigene neparvovec (Luxturna™) in der Augenheilkunde

Stand Januar 2019

Statement of the German Society of Ophthalmology (DOG), the German Retina Society (RG) and the Professional Association of German Ophthalmologists (BVA) on the therapeutic use of voretigene neparvovec-rzyl (Luxturna™) in ophthalmology

Situation January 2019

  • Leitlinien, Stellungnahmen und Empfehlungen
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Wenn bei Kleinkindern (3 bis 6 Jahre) Funktionstests z. T. nicht reproduzierbar durchgeführt werden können, aber eine ausreichende Dokumentation einer ONL nicht gelingt, kann von einem funktionalen Restgewebe ausgegangen werden [9].

  2. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&ved=0ahUKEwj1lsiF0eHbAhVJa1AKHdK8BaYQFghGMAM&url=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FCellularGeneTherapyProducts%2FApprovedProducts%2FUCM589541.pdf&usg=AOvVaw1_at1pmgjyPsqjlwnhOqN6.

Literatur

  1. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849–860. https://doi.org/10.1016/S0140-6736(17)31868-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bellingrath JS, Fischer MD (2015) Gene therapy as a treatment concept for inherited retinal diseases. Ophthalmologe 112:720–727. https://doi.org/10.1007/s00347-015-0121-8

    Article  CAS  PubMed  Google Scholar 

  3. Fischer MD (2016) On retinal gene therapy. Ophthalmologica 236:1–7. https://doi.org/10.1159/000445782

    Article  CAS  PubMed  Google Scholar 

  4. Thompson DA, Gyurus P, Fleischer LL, Bingham EL, McHenry CL, Apfelstedt-Sylla E, Zrenner E, Lorenz B, Richards JE, Jacobson SG, Sieving PA, Gal A (2000) Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci 41:4293–4299

    CAS  PubMed  Google Scholar 

  5. Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, Pierce E, Sallum J, Larsen M, Stieger K, Preising M, Weleber R, Yang P, Place E, Liu E, Schaefer G, DiStefano-Pappas J, Elci OU, McCague S, Wellman JA, High KA, Reape KZ (2018) The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2018.09.024

    Article  PubMed  Google Scholar 

  6. Lorenz B, Gyurus P, Preising M, Bremser D, Gu S, Andrassi M, Gerth C, Gal A (2000) Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci 41:2735–2742

    CAS  PubMed  Google Scholar 

  7. Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond TM (2008) A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. Invest Ophthalmol Vis Sci 49:5235–5242. https://doi.org/10.1167/iovs.07-1671

    Article  PubMed  PubMed Central  Google Scholar 

  8. Narfstrom K, Vaegan KM, Bragadottir R, Rakoczy EP, Seeliger M (2005) Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 111:39–48. https://doi.org/10.1007/s10633-005-3159-0

    Article  PubMed  Google Scholar 

  9. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J (2009) Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597–1605. https://doi.org/10.1016/S0140-6736(09)61836-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248. https://doi.org/10.1056/NEJMoa0802315

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komaromy AM, Hauswirth WW, Aguirre GD (2013) Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.1218933110

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239. https://doi.org/10.1056/NEJMoa0802268

    Article  CAS  PubMed  Google Scholar 

  13. Stieger K, Lorenz B (2018) Gentherapie bei degenerativen Erkrankungen der Netzhaut – ein Update. Z Prakt Augenheilkd 39:241–254.

    Google Scholar 

  14. Nelles M, Stieger K, Preising MN, Kruse J, Lorenz B (2015) Shared decision-making, control preferences and psychological well-being in patients with RPE65 deficiency awaiting experimental gene therapy. Ophthalmic Res 54:96–102. https://doi.org/10.1159/000435887

    Article  CAS  PubMed  Google Scholar 

  15. Lorenz B, Wabbels B, Wegscheider E, Hamel CP, Drexler W, Preising MN (2004) Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65. Ophthalmology 111:1585–1594. https://doi.org/10.1016/j.ophtha.2004.01.033

    Article  PubMed  Google Scholar 

  16. Paunescu K, Wabbels B, Preising MN, Lorenz B (2005) Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol 243:417–426. https://doi.org/10.1007/s00417-004-1020-x

    Article  PubMed  Google Scholar 

  17. Robson AG, Nilsson J, Li S, Jalali S, Fulton AB, Tormene AP, Holder GE, Brodie SE (2018) ISCEV guide to visual electrodiagnostic procedures. Doc Ophthalmol 136:1–26. https://doi.org/10.1007/s10633-017-9621-y

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kumaran N, Pennesi ME, Yang P, Trzupek KM, Schlechter C, Moore AT, Weleber RG, Michaelides M (1993) Leber congenital amaurosis / early-onset severe retinal dystrophy overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (Hrsg) GeneReviews((R)). University of Washington, Seattle

    Google Scholar 

  19. Jacobson SG, Aleman TS, Cideciyan AV, Heon E, Golczak M, Beltran WA, Sumaroka A, Schwartz SB, Roman AJ, Windsor EA, Wilson JM, Aguirre GD, Stone EM, Palczewski K (2007) Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci U S A 104:15123–15128. https://doi.org/10.1073/pnas.0706367104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lorenz B, Strohmayr E, Zahn S, Friedburg C, Kramer M, Preising M, Stieger K (2012) Chromatic pupillometry dissects function of the three different light-sensitive retinal cell populations in RPE65 deficiency. Invest Ophthalmol Vis Sci 53:5641–5652. https://doi.org/10.1167/iovs.12-9974

    Article  CAS  PubMed  Google Scholar 

  21. Roman AJ, Schwartz SB, Aleman TS, Cideciyan AV, Chico JD, Windsor EA, Gardner LM, Ying GS, Smilko EE, Maguire MG, Jacobson SG (2005) Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res 80:259–272. https://doi.org/10.1016/j.exer.2004.09.008

    Article  CAS  PubMed  Google Scholar 

  22. Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG (2007) Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas 28:N51–N56. https://doi.org/10.1088/0967-3334/28/8/N02

    Article  PubMed  Google Scholar 

  23. Jacobson SG, Aleman TS, Cideciyan AV, Roman AJ, Sumaroka A, Windsor EA, Schwartz SB, Heon E, Stone EM (2009) Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 50:2368–2375. https://doi.org/10.1167/iovs.08-2696

    Article  PubMed  Google Scholar 

  24. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal A (1997) Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet 17:194–197. https://doi.org/10.1038/ng1097-194

    Article  CAS  PubMed  Google Scholar 

  25. Fischer MD, Hickey DG, Singh MS, MacLaren RE (2016) Evaluation of an optimized injection system for retinal gene therapy in human patients. Hum Gene Ther Methods 27:150–158. https://doi.org/10.1089/hgtb.2016.086

    Article  CAS  PubMed  Google Scholar 

  26. Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, Ueffing M, Biel M, Wissinger B, Bartz-Schmidt KU, Peters T, Fischer MD, RDCC (2017) Superior retinal gene transfer and biodistribution profile of subretinal versus Intravitreal delivery of AAV8 in nonhuman primates. Invest Ophthalmol Vis Sci 58:5792–5801. https://doi.org/10.1167/iovs.17-22473

    Article  CAS  PubMed  Google Scholar 

  27. Reichel FF, Peters T, Wilhelm B, Biel M, Ueffing M, Wissinger B, Bartz-Schmidt KU, Klein R, Michalakis S, Fischer MD, Consortium R‑C (2018) Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients. Invest Ophthalmol Vis Sci 59:1910–1915. https://doi.org/10.1167/iovs.17-22494

    Article  CAS  PubMed  Google Scholar 

  28. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM (2012) AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4:120ra115. https://doi.org/10.1126/scitranslmed.3002865

    Article  CAS  Google Scholar 

  29. Willett K, Bennett J (2013) Immunology of AAV-mediated gene transfer in the eye. Front Immunol 4:261. https://doi.org/10.3389/fimmu.2013.00261

    Article  PubMed  PubMed Central  Google Scholar 

  30. Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, Banfi S, Surace EM, Sun J, Acerra C, Wright JF, Wellman J, High KA, Auricchio A, Bennett J, Simonelli F (2013) Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120:1283–1291. https://doi.org/10.1016/j.ophtha.2012.11.048

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ashtari M, Zhang H, Cook PA, Cyckowski LL, Shindler KS, Marshall KA, Aravand P, Vossough A, Gee JC, Maguire AM, Baker CI, Bennett J (2015) Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis. Sci Transl Med 7:296ra110. https://doi.org/10.1126/scitranslmed.aaa8791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, Hauswirth WW (2015) Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 372:1920–1926. https://doi.org/10.1056/NEJMoa1412965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Redaktionskomitee

Prof. Dr. med. Dominik Fischer, Tübingen (federführend)

Prof. Dr. med. Bernd Bertram, Aachen

Prof. Dr. med. Ulrich, Kellner, Siegburg

Prof. Dr. med. Hansjuergen Agostini, Freiburg im Breisgau

Prof. Dr. med. Birgit Lorenz, Gießen

Dr. med. Philipp Herrmann, Bonn

Author information

Authors and Affiliations

    Consortia

    Deutsche Ophthalmologische Gesellschaft (DOG)

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)

    Retinologische Gesellschaft e. V. (RG)

    Ethics declarations

    Interessenkonflikt

    Siehe Tab. 2 im Anhang.

    Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

    Additional information

    Diese Stellungnahme erscheint ebenfalls in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, Georg Thieme Verlag, Stuttgart.

    Anhang

    Anhang

    Tab. 2 Tabellarische Zusammenfassung der Erklärungen über Interessenkonflikte Stellungnahme zur therapeutischen Anwendung von voretigene neparvovec (Luxturna™) in der Augenheilkunde
    Full size table

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Deutsche Ophthalmologische Gesellschaft (DOG)., Berufsverband der Augenärzte Deutschlands e. V. (BVA). & Retinologische Gesellschaft e. V. (RG). Stellungnahme von DOG, RG und BVA zur therapeutischen Anwendung von voretigene neparvovec (Luxturna™) in der Augenheilkunde. Ophthalmologe 116, 524–533 (2019). https://doi.org/10.1007/s00347-019-0885-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00347-019-0885-3

    Search

    Navigation